Microbiota Profiling for Precision Medicine

ISBN-13: 9789819521036 / Angielski / Twarda / 2025 / 460 str.

Opis

This book provides an in-depth exploration of microbiota profiling and precision medicine, including the underlying mechanisms, delivery methods, treatment strategies, and the impact of biomarker-targeted drug delivery. It incorporates the latest research findings, such as biomarker-targeted drug delivery, clinical assessment and diagnosis, and therapeutic approaches. The book offers a comprehensive overview of the latest developments in biomarker-targeted drug delivery strategies. It addresses the challenges faced by healthcare professionals, offering actionable strategies for effective multidisciplinary care, along with patient and family perspectives, coping mechanisms, and ways to improve quality of life. By combining scientific knowledge, clinical expertise, and patient insights, the book enhances understanding, diagnosis, and treatment options for these complex conditions. These qualities distinguish it from existing publications and make it a valuable resource for readers seeking a thorough and engaging overview of this subject.The chapters cover a broad range of topics, including recent advances in microbiota profiling techniques, microbiota's role in drug metabolism and toxicity, and its immunomodulatory effects. Special focus is given to the involvement of microbiota in neurodegenerative diseases such as Alzheimer's and Parkinson's, emphasizing the therapeutic potential of microbiome-targeted strategies. The authors provide expert analysis on integrating microbiota-derived data with innovative tools like nanotechnology and machine learning to improve drug delivery systems. Readers will also gain practical insights from case studies on microbiota-informed therapies for cancer, autoimmune conditions, and gastrointestinal disorders. This book is essential for researchers, clinicians, academicians, and students working in microbiome science, pharmacology, biotechnology, and precision medicine. It addresses key questions such as biomarker validation, data integration, and the ethical considerations necessary for the clinical use of microbiome-based therapies.